Clinical Trial

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

Study acronym: Perfume
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is an open-label, parallel, 2-cohort, multicenter, investigator-initiated Phase 2 trial to evaluate the efficacy and safety of binimetinib in patients with advanced or recurrent low-grade glioma or pancreatic cancer harboring BRAF fusion/rearrangement.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-11-28.
Trial Details
NCT Number NCT06159478
Lead Sponsor National Cancer Center, Japan
Collaborators: Ono Pharmaceutical Co., Ltd.
Conditions Low-grade Glioma, Pancreatic Cancer
Enrollment 32 participants
Start Date 2023-03-29
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2023-12-13